Clinical trial · Observational
Daily Target Guided Radiation Therapy Using the Calypso 4D Localization System in Patients Who Have Had a Prostatectomy for Prostate Cancer
Post-prostatectomy Daily Target Guided Radiotherapy Using Real-Time, State-of-the-Art Motion Tracking With the Calypso 4D Localization System: A Feasibility Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the daily use of a unique daily organ tracking system on target localization in patients treated with radiation therapy after radical prostatectomy for prostate cancer. Improved coverage of the target volume with radiotherapy could result in improved cancer control rates and decreased coverage of surrounding structures potentially decreasing treatment toxicity.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Interfraction prostate bed motion
- timeFrame
- Approximately 7.5 weeks (36-39 fractions per pt.)
- description
- For each fraction, measurements from the registered CTV (clinical target volume) at the midline will be obtained to structures at 3 points to assess for the degree of motion. 1. Inferior (defined as 8 mm below VUA) 2. Superior (top of seminal vesicle remnant or superior most CTV slice) 3. Middle (defined as the slice equally distant from the inferior and superior slices above)
- measure
- Intrafraction prostate bed motion
- timeFrame
- Approximately 7.5 weeks (36-39 fractions per pt.)
- description
- Calypso session reports measuring intrafraction motion in x,y,z axis will be recorded and analyzed.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate initially managed with prostatectomy with a detectable PSA, positive surgical margins, or extra-prostatic extension. * Ability to comply with study schedule * Age 40 or older * Zubrod PS 0 or 1 (appendix 1) * Signed informed consent Exclusion Criteria: * Node positive or metastatic prostate cancer * History of prior pelvic radiotherapy * History of abdominoperineal resection * History of inflammatory bowel disease or connective tissue disease * History of bleeding disorder or any active anticoagulant or anti-platelet medication which cannot be discontinued safely for transponder placement. * PT or INR outside normal range for institution * Active implanted devices such as cardiac pacemakers and automatic defibrillators. * Prosthetic implants in the pelvic region that contain metal or conductive materials (eg., an artificial hip). * Patients with maximum anterior-posterior separation through the torso minus the height of the center of the prostate greater than 17 cm (technical reason for Calypso System, see appendix 5). * History of HIV infection
References
Publications (0)
Data not yet available